CompletedPhase 2NCT04563923
Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody
Studying Bullous pemphigoid
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Principal Investigator
- Passeron Thierry, PhDCHU de Nice, Dermatologie
- Intervention
- Avdoralimab (IPH5401)(drug)
- Enrollment
- 15 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2024
Study locations (4)
- CHU de Nice- Dermatologie, Nice, Alpes-Maritimes, France
- APHM, Timone, Marseille, Bouche Du Rhône, France
- APHM, Hôpital Nord, Marseille, Bouches du rhône, France
- CHU Montpellier, Dermatologie, Montpellier, Herault, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04563923 on ClinicalTrials.govOther trials for Bullous pemphigoid
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06291350Peridontal and Intestinal Microbiota in Patients With Gingival Scarring PemphigoidCentre Hospitalier Universitaire de Nice
- RECRUITINGNANCT06479018Deciphering IL-17-dependant Inflammatory Response in Bullous PemphigoidCHU de Reims
- RECRUITINGNCT04198740Proteomic and Metabolomic Lacrimal Fingerprint in Diverse Pathologies of the Ocular SurfaceCentre hospitalier de l'Université de Montréal (CHUM)
- RECRUITINGPHASE3NCT03295383Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane PemphigoidUniversity Hospital, Rouen